{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:39:35Z","timestamp":1793151575867,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00392-019-01511-0","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T06:02:37Z","timestamp":1563516157000},"page":"315-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort"],"prefix":"10.1007","volume":"109","author":[{"given":"Alexander","family":"Peikert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Manhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Willecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Zehender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"von zur M\u00fchlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-3297","authenticated-orcid":false,"given":"Andreas","family":"Zirlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Stachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"issue":"6917","key":"1511_CR1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P Libby","year":"2002","unstructured":"Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868\u2013874","journal-title":"Nature"},{"issue":"16","key":"1511_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685\u20131695","journal-title":"N Engl J Med"},{"issue":"2","key":"1511_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2217\/17520363.1.2.229","volume":"1","author":"D Conen","year":"2007","unstructured":"Conen D, Ridker PM (2007) Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Biomark Med 1(2):229\u2013241","journal-title":"Biomark Med"},{"issue":"3","key":"1511_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","volume":"29","author":"KK Ray","year":"2009","unstructured":"Ray KK et al (2009) Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29(3):424\u2013430","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 12A","key":"1511_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.amjmed.2005.09.014","volume":"118","author":"J Rouleau","year":"2005","unstructured":"Rouleau J (2005) Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) trial. Am J Med 118(Suppl 12A):28\u201335","journal-title":"Am J Med"},{"issue":"21","key":"1511_CR6","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195\u20132207","journal-title":"N Engl J Med"},{"issue":"1","key":"1511_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","volume":"118","author":"PM Ridker","year":"2016","unstructured":"Ridker PM (2016) From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 118(1):145\u2013156","journal-title":"Circ Res"},{"issue":"10","key":"1511_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue ML et al (2014) Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312(10):1006\u20131015","journal-title":"JAMA"},{"issue":"12","key":"1511_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131","journal-title":"N Engl J Med"},{"key":"1511_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2017","unstructured":"Ridker PM et al (2017) Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391:319\u2013328","journal-title":"Lancet"},{"issue":"4","key":"1511_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","volume":"162","author":"PM Ridker","year":"2011","unstructured":"Ridker PM et al (2011) Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J 162(4):597\u2013605","journal-title":"Am Heart J"},{"issue":"5","key":"1511_CR12","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0735-1097(01)01591-1","volume":"38","author":"MW Hwang","year":"2001","unstructured":"Hwang MW et al (2001) Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 38(5):1546\u20131553","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"1511_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","volume":"132","author":"EA Bohula","year":"2015","unstructured":"Bohula EA et al (2015) Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132(13):1224\u20131233","journal-title":"Circulation"},{"key":"1511_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","volume":"266","author":"AK Gitt","year":"2017","unstructured":"Gitt AK et al (2017) Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the dyslipidemia international study II. Atherosclerosis 266:158\u2013166","journal-title":"Atherosclerosis"},{"issue":"5","key":"1511_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00392-017-1193-z","volume":"107","author":"KM Fox","year":"2018","unstructured":"Fox KM et al (2018) Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol 107(5):380\u2013388","journal-title":"Clin Res Cardiol"},{"issue":"9753","key":"1511_CR16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"CT Trialists","year":"2010","unstructured":"Trialists CT et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681","journal-title":"Lancet"},{"issue":"16","key":"1511_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489\u20131499","journal-title":"N Engl J Med"},{"issue":"18","key":"1511_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS et al (2017) Evolocumab and Clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713\u20131722","journal-title":"N Engl J Med"},{"key":"1511_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jacl.2018.03.088","volume":"12","author":"PM Ridker","year":"2018","unstructured":"Ridker PM et al (2018) Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. J Clin Lipidol 12:958\u2013965","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1511_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa042000","volume":"352","author":"SE Nissen","year":"2005","unstructured":"Nissen SE et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352(1):29\u201338","journal-title":"N Engl J Med"},{"issue":"39","key":"1511_CR21","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL et al (2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999\u20133058","journal-title":"Eur Heart J"},{"issue":"4","key":"1511_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","volume":"106","author":"H Soran","year":"2017","unstructured":"Soran H, Dent R, Durrington P (2017) Evidence-based goals in LDL-C reduction. Clin Res Cardiol 106(4):237\u2013248","journal-title":"Clin Res Cardiol"},{"key":"1511_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","volume":"138","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD et al (2018) Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation 138:141\u2013149","journal-title":"Circulation"},{"key":"1511_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","volume":"138","author":"EA Bohula","year":"2018","unstructured":"Bohula EA et al (2018) Inflammatory and cholesterol risk in the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in patients with elevated risk). Circulation 138:131\u2013140","journal-title":"Circulation"},{"issue":"4","key":"1511_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/ATVBAHA.114.304960","volume":"35","author":"JW McEvoy","year":"2015","unstructured":"McEvoy JW et al (2015) Relationship of cigarette smoking with inflammation and subclinical vascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 35(4):1002\u20131010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1511_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine B et al (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323(4):236\u2013241","journal-title":"N Engl J Med"},{"issue":"4","key":"1511_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1570161115666170404121619","volume":"15","author":"S Kang","year":"2017","unstructured":"Kang S et al (2017) Relationship of high-sensitivity C-reactive protein concentrations and systolic heart failure. Curr Vasc Pharmacol 15(4):390\u2013396","journal-title":"Curr Vasc Pharmacol"},{"issue":"8","key":"1511_CR28","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.amjcard.2018.07.002","volume":"122","author":"CR Trankle","year":"2018","unstructured":"Trankle CR et al (2018) Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein. Am J Cardiol 122(8):1366\u20131370","journal-title":"Am J Cardiol"},{"issue":"7","key":"1511_CR29","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","volume":"116","author":"DL Mann","year":"2015","unstructured":"Mann DL (2015) Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 116(7):1254\u20131268","journal-title":"Circ Res"},{"issue":"4","key":"1511_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00392-017-1195-x","volume":"107","author":"S Radenovic","year":"2018","unstructured":"Radenovic S et al (2018) Systemic inflammation and functional capacity in elderly heart failure patients. Clin Res Cardiol 107(4):362\u2013367","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"1511_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/157016111793744788","volume":"9","author":"T Ishibashi","year":"2011","unstructured":"Ishibashi T, Takeishi Y (2011) Ezetimibe and vascular inflammation. Curr Vasc Pharmacol 9(1):99\u2013108","journal-title":"Curr Vasc Pharmacol"},{"issue":"1\u20132","key":"1511_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000357953","volume":"93","author":"L Qin","year":"2014","unstructured":"Qin L et al (2014) Anti-inflammatory activity of ezetimibe by regulating NF-\u03baB\/MAPK pathway in THP-1 macrophages. Pharmacology 93(1\u20132):69\u201375","journal-title":"Pharmacology"},{"issue":"8","key":"1511_CR33","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/j.1476-5381.2008.00091.x","volume":"156","author":"D G\u00f3mez-Garre","year":"2009","unstructured":"G\u00f3mez-Garre D et al (2009) Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 156(8):1218\u20131227","journal-title":"Br J Pharmacol"},{"issue":"12","key":"1511_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","volume":"4","author":"MK Jain","year":"2005","unstructured":"Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4(12):977\u2013987","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1511_CR35","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/j.1476-5381.2009.00612.x","volume":"159","author":"M Jougasaki","year":"2010","unstructured":"Jougasaki M et al (2010) Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase\/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159(6):1294\u20131303","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1511_CR36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.atherosclerosis.2007.07.031","volume":"197","author":"K Mausner-Fainberg","year":"2008","unstructured":"Mausner-Fainberg K et al (2008) The effect of HMG-CoA reductase inhibitors on naturally occurring CD4\u2009+\u2009CD25\u2009+\u2009T cells. Atherosclerosis 197(2):829\u2013839","journal-title":"Atherosclerosis"},{"issue":"3","key":"1511_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1017\/S0029665110001539","volume":"69","author":"R Estruch","year":"2010","unstructured":"Estruch R (2010) Anti-inflammatory effects of the Mediterranean diet: the experience of the PREDIMED study. Proc Nutr Soc 69(3):333\u2013340","journal-title":"Proc Nutr Soc"},{"key":"1511_CR38","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2018","unstructured":"Ridker PM et al (2018) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380:752\u2013762","journal-title":"N Engl J Med"},{"issue":"6","key":"1511_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","volume":"36","author":"AC Morton","year":"2015","unstructured":"Morton AC et al (2015) The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. Eur Heart J 36(6):377\u2013384","journal-title":"Eur Heart J"},{"issue":"4","key":"1511_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM et al (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61(4):404\u2013410","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01511-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01511-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T19:12:57Z","timestamp":1595013177000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01511-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01511-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Andreas Clemens is beside his scientific activities at the University Heart Center employee and shareholder at Novartis Pharma AG. There is no other conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}